On June 25, 2025, Entero Therapeutics, Inc. received an extension from Nasdaq until October 8, 2025, to meet the minimum stockholders' equity requirement after reporting a deficiency of ($3,876,738) compared to the required minimum of $2.5 million. Failure to comply may lead to delisting from the Nasdaq Capital Market.